What is synAllergy?
synAllergy provides a comprehensive resource designed to assist healthcare providers in appealing rejected insurance claims. The company's core offering enables clinics to integrate skin allergy testing and immunotherapy services seamlessly into their existing operations, requiring no additional physical space. Through a turn-key process, synAllergy facilitates rapid implementation, with practices becoming operational in as little as two weeks. The service includes extensive training for medical staff, covering both skin allergy testing procedures and immunotherapy preparation, with a focus on efficiency and safety. Ongoing support and educational resources are provided to ensure successful program delivery.
How much funding has synAllergy raised?
synAllergy has raised a total of $12K across 1 funding round:
Debt
$12K
Debt (2021): $12K with participation from PPP
Key Investors in synAllergy
PPP
Public-Private Partnership
What's next for synAllergy?
With the recent capital secured, synAllergy is poised to enhance its service offerings and expand its client base. The strategic investment will likely fuel advancements in its claim appeal technology and broaden the reach of its allergy testing and immunotherapy solutions. Future developments may include further integration with electronic health record systems and enhanced analytics for claim appeal success rates. The company's focus on operational efficiency and provider support suggests a continued emphasis on empowering healthcare practices to optimize revenue cycles and patient care.
See full synAllergy company page
